Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading

Definium Therapeutics (NASDAQ:DFTX) had its price target lifted by analysts at JonesTrading from $74.00 to $90.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. JonesTrading’s target price suggests a potential upside of 103.94% from the company’s current price.

Several other research firms have also commented on DFTX. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Needham & Company LLC raised their price objective on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Royal Bank Of Canada raised their price target on Definium Therapeutics from $57.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $62.69.

Definium Therapeutics Trading Up 3.1%

NASDAQ:DFTX traded up $1.34 during trading hours on Thursday, hitting $44.13. The company had a trading volume of 1,290,696 shares, compared to its average volume of 2,293,201. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. Definium Therapeutics has a 52 week low of $8.70 and a 52 week high of $49.70. The company has a market capitalization of $4.40 billion, a PE ratio of -12.87 and a beta of 2.23. The stock has a 50-day moving average price of $39.06 and a 200 day moving average price of $26.52.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, equities research analysts predict that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Activity

In other news, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares in the company, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert Barrow sold 29,208 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer directly owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 48,096 shares of company stock worth $2,165,763. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of DFTX. Bank of New York Mellon Corp grew its position in Definium Therapeutics by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after acquiring an additional 24,349 shares in the last quarter. Caxton Associates LLP acquired a new position in Definium Therapeutics during the 3rd quarter worth $126,000. Sender Co & Partners Inc. purchased a new stake in Definium Therapeutics during the 3rd quarter worth about $305,000. Scientech Research LLC acquired a new stake in Definium Therapeutics in the 3rd quarter valued at about $286,000. Finally, Mercer Global Advisors Inc. ADV raised its position in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after purchasing an additional 2,079 shares in the last quarter. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive topline results from the Phase 3 Voyage study. DT120 ODT produced a 5.4-point improvement versus placebo on the Hamilton Anxiety Rating Scale, strengthening the case for the therapy’s efficacy and potential regulatory and commercial value. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: The results represent the second positive Phase 3 study for DT120, prompting reports that the drug could potentially disrupt the anxiety-treatment market. The data also support investor expectations for DT120 in more than one indication and a possible catalyst in September 2026. Definium Therapeutics Announces Positive Topline Results
• Positive Sentiment: Several firms raised their price targets and maintained bullish ratings: Robert W. Baird lifted its target to $75 with an “outperform” rating, Wells Fargo raised its target to $72 with an “overweight” rating, and RBC increased its target to $66 while also rating the stock “outperform.” Needham separately raised its target to $66 and kept a “buy” rating. These targets imply substantial potential upside from the stock’s recent level near $44. Analyst price-target changes
• Neutral Sentiment: Trading in DFTX was temporarily halted for news pending on August 12, highlighting the market-moving nature of the clinical announcement. The stock is trading close to its 52-week high, which may increase volatility as investors assess the data and upcoming regulatory milestones.
• Negative Sentiment: Definium remains loss-making, and HC Wainwright reduced its EPS forecasts across 2026–2030, including lowering its 2026 estimate to a $3.05 loss per share and its 2028 estimate to $0.33 from $0.77. The company’s earlier quarterly loss also missed consensus, leaving execution, cash requirements and commercialization risks as important counterweights to the positive trial results.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.